PolyPid Ltd.
PYPD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PYPD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PYPD
PolyPid Ltd. is a Phase 3 clinical-stage biopharmaceutical company developing D-PLEX100, a locally administered, prolonged-release therapy for preventing surgical site infections, with no commercial revenue and a going concern risk.
Key risk: Going concern risk
Market Cap
$103.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 5 clinical trials for PolyPid Ltd..
PolyPid Ltd. is a Phase 3 clinical-stage biopharmaceutical company developing D-PLEX100, a locally administered, prolonged-release therapy for preventing surgical site infections, with no commercial revenue and a going concern risk.
- PolyPid is a Phase 3 clinical-stage biopharmaceutical company focused on targeted, locally administered and prolonged-release therapeutics [sec · filed 2025-02-26].
- As of February 19, 2026, the company had cash, cash equivalents and short-term deposits of $12.7 million [sec · filed 2026-02-25].
- The company has not generated any revenues from commercial sales and does not expect to generate revenue for the foreseeable future [sec · filed 2026-02-25].
- As of December 31, 2024, the accumulated deficit was $267.3 million [sec · filed 2025-02-26].
- The company expects to need substantial additional financing to fund operations and has expressed substantial doubt about its ability to continue as a going concern [sec · filed 2026-02-25].
What works
- The company is advancing D-PLEX100 through a Phase 3 clinical trial (SHIELD II) for the prevention of surgical site infections in abdominal colorectal surgery, targeting a large unmet medical need [sec · filed 2025-02-26].
- PolyPid maintains its own commercial-scale cGMP manufacturing facility, which could provide operational control and cost advantages if the product is approved [sec · filed 2026-02-25].
- The company has secured some non-dilutive funding from the Israel Innovation Authority (IIA) and FP7, totaling $2.2 million as of 2024 [sec · filed 2025-02-26].
What to weigh
- PolyPid has no approved products or commercial revenue and expects to continue incurring significant operating losses for the foreseeable future [sec · filed 2026-02-25].
- The company faces substantial doubt about its ability to continue as a going concern and will require significant additional financing, which may not be available on acceptable terms [sec · filed 2026-02-25].
- Clinical trial enrollment is a key risk; delays or inability to enroll patients could increase costs and delay development [sec · filed 2025-02-26].
- The company operates in a competitive landscape with other therapies targeting the same indications, which could impact patient enrollment and market adoption [sec · filed 2025-02-26].
From the filings
Quoted directly from source documents.
The company has not generated any revenues from commercial sales and does not expect to generate revenue for the foreseeable future.
“we have not generated any revenues from the commercial sale of our product candidates, and we do not expect to generate revenue for the foreseeable future.”
SEC filings · February 25, 2026
As of February 19, 2026, the company had cash, cash equivalents and short-term deposits of $12.7 million.
“As of February 19, 2026, we had cash, cash equivalents and short-term deposits of $12.7 million.”
SEC filings · February 25, 2026
The company has an accumulated deficit of $267.3 million as of December 31, 2024.
“As of December 31, 2024, we had an accumulated deficit of $267.3 million.”
SEC filings · February 26, 2025
There is substantial doubt about the company's ability to continue as a going concern.
“This may raise substantial doubts about our ability to continue as a going concern.”
SEC filings · February 25, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern; needs significant additional financing [sec · filed 2026-02-25].
- No commercial revenue — No approved products or revenue; expects to incur losses for the foreseeable future [sec · filed 2026-02-25].
- Clinical trial enrollment delays — Delays or inability to enroll patients could increase costs and delay development [sec · filed 2025-02-26].
- Competitive landscape — Competes with other therapies for same indications, affecting enrollment and market share [sec · filed 2025-02-26].
What to watch
- Progress and results of the SHIELD II Phase 3 clinical trial for D-PLEX100 [sec · filed 2025-02-26].
- Timing of NDA submission to the FDA and marketing authorization application to the EMA [sec · filed 2026-02-25].
- Ability to raise additional capital through equity, debt, or strategic partnerships [sec · filed 2026-02-25].
- Cash runway and any updates on cash position beyond February 19, 2026 [sec · filed 2026-02-25].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run PolyPid Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PolyPid Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 0.2%
- Days to cover
- 0.5
- Shares short
- 30,140
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PYPD short interestFrequently asked questions
What is the AI investment thesis for PolyPid Ltd.?
PolyPid Ltd. is a Phase 3 clinical-stage biopharmaceutical company developing D-PLEX100, a locally administered, prolonged-release therapy for preventing surgical site infections, with no commercial revenue and a going concern risk.
Who is the CEO of PolyPid Ltd.?
Ms. Dikla Czaczkes Akselbrad is the chief executive officer of PolyPid Ltd. (PYPD).
Where is PolyPid Ltd. headquartered?
PolyPid Ltd. (PYPD) is headquartered in Petah Tikva, Israel.
What therapeutic areas does PolyPid Ltd. focus on?
PolyPid Ltd. develops therapies across Oncology, Cardiovascular, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.